Open collaboration with academia, biotech and pharma
- R&D R&D at the heart of our mission to develop global medicines for treatment of incurable diseases.
- Pipeline Specalized in antibody research for treatment of autoimmune disease, dry eye diseases, and immuno-oncology drugs.
- People We strive to make healthier, happier and better today.
- Compliance and Ethics We act with high ethics.
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business UpdateIn Detail
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of BatoclimabIn Detail
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in ChinaIn Detail